IP Library Granted Patent US 7,736,854
Granted Patent B2
US 7,736,854 · App. 11/606,518 · Granted Jun 15, 2010

Methods of detection of a target nucleic acid sequence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,736,854
App. No.
11/606,518
Granted
Jun 15, 2010
Kind
B2
Abstract

The present invention is directed to methods of generating a signal indicative of the presence of a target nucleic acid in a sample by forming a cleavage structure comprising duplex and single-stranded nucleic acid by incubating a sample comprising a target nucleic acid with a thermostable nucleic acid polymerase substantially lacking 5′ to 3′ exonuclease activity and cleaving said cleavage structure with a thermostable Fen nuclease lacking 5′ to 3′ synthetic activity to generate a signal.

Claims (16)

1. A method of generating a signal indicative of the presence of a target nucleic acid in a sample, comprising:

in the same reaction vessel, forming a cleavage structure comprising duplex and single-stranded nucleic acid by incubating a sample comprising a target nucleic acid with a thermostable nucleic acid polymerase substantially lacking 5′ to 3′ exonuclease activity and cleaving said cleavage structure with a thermostable Fen nuclease lacking 5′ to 3′ synthetic activity to generate a signal, wherein generation of said signal is indicative of the presence of a target nucleic acid in said sample.

2. A method of detecting and/or measuring a target nucleic acid in a sample, comprising:

in the same reaction vessel, forming a cleavage structure comprising duplex and single-stranded nucleic acid, wherein said single stranded nucleic acid comprises a 5′ flap, by incubating a sample comprising a target nucleic acid with a thermostable nucleic acid polymerase substantially lacking 5′ to 3′ exonuclease activity and cleaving said cleavage structure with a thermostable Fen nuclease substantially lacking 5′ to 3′ synthetic activity to release a nucleic acid fragment, anti detecting and/or measuring the release of said fragment as an indication of the presence of the target in the sample.

3. The method of claim 1 or 2 , wherein said method comprises, in said reaction vessel, a pair of amplification primers complementary with said target nucleic acid to permit amplification of a sequence of said target nucleic acid between said primers.

4. The method of claim 3 , wherein said method comprises, in said reaction vessel, one or more dNTPs.

5. The method of claim 3 , wherein said method comprises, in said reaction vessel, an oligonucleotide that specifically hybridizes to a region of the target nucleic acid between said amplification primers.

6. The method of claims 1 or 2 , wherein said method comprises, in said reaction vessel, said thermostable Fen nuclease selected from the group consisting of Fen nuclease enzyme of Archaeglobus fulgidus, Methanococcus jannaschii, Pyrococcus furiosus, and Pyrococcus horikoshii.

7. The method of claims 1 or 2 , wherein said method comprises, in said reaction vessel, a thermostable polymerase selected from the group consisting of Pfu, Pfu-exo, Taq, Taq-exo, Deep vent and Deep vent exo.

8. The method of claims 1 or 2 , wherein a cleavage structure is formed prior to the addition of said Fen nuclease, said cleavage structure comprising a 5′ flap, and said Fen nuclease cleaves said 5′ flap of said cleavage structure.

9. The method of claim 8 , wherein said 5′ flap comprises a label comprising a first member of a pair of interactive labels effectively positioned to quench the generation of a detectable signal, the first and second members of said pair being separable by a site susceptible to Fen nuclease cleavage, thereby allowing the nuclease activity of the Fen nuclease to separate the first interactive signal generating labeled moiety from the second interactive signal generating labeled moiety by cleaving at said site susceptible to Fen nuclease, thereby generating a signal.

10. The method of claim 9 , wherein said pair of interactive labels comprises a quencher moiety and a fluorescent moiety.

11. The method of claim 3 , wherein said amplification primers are between about 10 to 100 nucleotides in length.

12. The method of claim 3 , wherein said amplification primers are between about 17-50 nucleotides in length.

13. The method of claim 3 , wherein said amplification primers are between about 17-45 nucleotides in length.

14. The method of claim 1 , wherein said Fen nuclease is a Fen-1 nuclease.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
EIGHTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Mar 26, 2009
From: CYTYC CORPORATION; HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERSL.P.
Reel/Frame 022456/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: STRATAGENE CALIFORNIA
To: HOLOGIC INC.
Reel/Frame 021976/0268 →